Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
Provided By GlobeNewswire
Last update: Mar 28, 2025
WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the fiscal year ended December 31, 2024, and recent corporate updates.
Read more at globenewswire.com
